230 related articles for article (PubMed ID: 20702523)
1. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
J Clin Endocrinol Metab; 2010 Nov; 95(11):4943-50. PubMed ID: 20702523
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
Festen DA; van Toorenenbergen A; Duivenvoorden HJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2007 Apr; 92(4):1549-54. PubMed ID: 17264186
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
8. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
9. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.
Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
Endocr J; 2018 Nov; 65(11):1127-1137. PubMed ID: 30185718
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
Höybye C; Hilding A; Jacobsson H; Thorén M
Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
[TBL] [Abstract][Full Text] [Related]
11. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome.
Marzullo P; Marcassa C; Minocci A; Campini R; Eleuteri E; Gondoni LA; Aimaretti G; Sartorio A; Scacchi M; Grugni G
J Clin Endocrinol Metab; 2015 May; 100(5):2106-14. PubMed ID: 25710568
[TBL] [Abstract][Full Text] [Related]
12. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.
Gondoni LA; Vismara L; Marzullo P; Vettor R; Liuzzi A; Grugni G
J Endocrinol Invest; 2008 Sep; 31(9):765-72. PubMed ID: 18997487
[TBL] [Abstract][Full Text] [Related]
15. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment.
de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC
J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197
[TBL] [Abstract][Full Text] [Related]
18. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
19. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
[TBL] [Abstract][Full Text] [Related]
20. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
